CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $75 to $150, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) entered into privately negotiated transactions to repurchase about $179.4 million of its existing 2.25% convertible senior...
Neurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...
| Address | 12780 El Camino Real San Diego, California 92130 |
| Phone | +1.858.617.7600 |
| Number of Employees | 585 |
| Recent SEC Filing | 06/29/2022 4 |
| Chief Executive Officer & Director | Kevin Charles Gorman |
| Vice President-Information Technology & Operations | Bill Wilson |
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Research Officer | Dimitri E. Grigoriadis |
| Price Open | $97.61 |
| Previous Close | $98.30 |
| 52 Week Range | $71.88 - 108.02 |
| Market Capitalization | $9.2 B |
| Shares Outstanding | 95.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 137.85 |
| Earnings per Share | $1.21 |
| Beta vs. S&P 500 | N/A |
| Revenue | $451.2 M |
| Net Profit Margin | 5.91% |
| Return on Equity | 5.30% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
